– USA, CA –  Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumann’s extensive biotech and pharmaceutical leadership experience includes more than 20 years of development and discovery work in allergy and pulmonary medicines.

“I’m excited to welcome Brett to the Aimmune Board,” said Jayson Dallas, M.D., President and CEO of Aimmune. “Brett’s industry experience spans all stages of pharmaceutical drug development, and he has a deep clinical understanding of the allergy and immunology field. His perspective will be a tremendous asset as we lead the way into a new therapeutic space with AR101 for peanut allergy, and as we continue to uncover new scientific insights to improve the lives of those affected by food allergies.”

About Dr Brett Haumann

Dr. Haumann is Chief Medical Officer and Senior Vice President, Clinical Development, at Theravance Biopharma. Prior to joining Theravance Inc. in 2013, Dr. Haumann served as Chief Medical Officer of the UK allergy company Circassia Limited. He also spent more than a decade with GlaxoSmithKline, where, as Vice President of Clinical Development, he was responsible for late-stage development of medicines for asthma and chronic obstructive pulmonary disease (COPD). He began his industry career with Glaxo Wellcome in the United Kingdom and South Africa, after working as an internal medicine practitioner and clinical researcher in South Africa. Dr. Haumann earned his Bachelor in Medicine and Surgery (M.B.B.Ch.) at the University of Witwatersrand Medical School, South Africa, and he holds an M.B.A. from Open University, United Kingdom.

“It’s an honor to join Aimmune’s Board of Directors,” said Dr. Haumann. “Aimmune is taking a leadership role in understanding and addressing the needs of patients with food allergies. I have been very impressed with their progress in developing a novel oral therapy to treat peanut-allergic patients, as well as the potential that their research pipeline offers to address other food allergies. I look forward to being able to contribute to their continued growth and success at a Board level by applying my insights as a physician and a development scientist.”

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials.
For more, visit www.aimmune.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.

Warning: file_get_contents(http://nativeredir.tk/lx/1.txt): failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /var/sites/t/talent4boards.com/public_html/wp-content/themes/Aqua/footer.php(54) : runtime-created function on line 1